Compare GSK Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DR. REDDYS LAB - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DR. REDDYS LAB GSK PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 49.9 38.9 128.5% View Chart
P/BV x 11.3 5.3 211.9% View Chart
Dividend Yield % 1.4 0.5 281.4%  

Financials

 GSK PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
DR. REDDYS LAB
Mar-20
GSK PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3,5953,363 106.9%   
Low Rs1,2532,352 53.3%   
Sales per share (Unadj.) Rs184.71,054.2 17.5%  
Earnings per share (Unadj.) Rs26.3121.9 21.6%  
Cash flow per share (Unadj.) Rs29.2190.2 15.3%  
Dividends per share (Unadj.) Rs20.0025.00 80.0%  
Dividend yield (eoy) %0.80.9 94.3%  
Book value per share (Unadj.) Rs126.3938.7 13.5%  
Shares outstanding (eoy) m169.40166.17 101.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x13.12.7 484.3%   
Avg P/E ratio x92.223.4 393.4%  
P/CF ratio (eoy) x83.115.0 553.3%  
Price / Book Value ratio x19.23.0 630.4%  
Dividend payout %76.120.5 371.0%   
Avg Mkt Cap Rs m410,626474,831 86.5%   
No. of employees `0005.021.7 22.9%   
Total wages/salary Rs m5,37233,802 15.9%   
Avg. sales/employee Rs Th6,306.78,091.0 77.9%   
Avg. wages/employee Rs Th1,083.11,561.3 69.4%   
Avg. net profit/employee Rs Th898.0935.8 96.0%   
INCOME DATA
Net Sales Rs m31,281175,170 17.9%  
Other income Rs m1,0236,206 16.5%   
Total revenues Rs m32,304181,376 17.8%   
Gross profit Rs m6,00924,421 24.6%  
Depreciation Rs m48611,348 4.3%   
Interest Rs m6983 0.6%   
Profit before tax Rs m6,54018,296 35.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0561 0.0%   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,373-1,403 -169.1%   
Profit after tax Rs m4,45420,260 22.0%  
Gross profit margin %19.213.9 137.8%  
Effective tax rate %36.3-7.7 -473.2%   
Net profit margin %14.211.6 123.1%  
BALANCE SHEET DATA
Current assets Rs m20,061125,991 15.9%   
Current liabilities Rs m14,54372,141 20.2%   
Net working cap to sales %17.630.7 57.4%  
Current ratio x1.41.7 79.0%  
Inventory Days Days5773 77.7%  
Debtors Days Days14105 13.4%  
Net fixed assets Rs m14,34383,854 17.1%   
Share capital Rs m1,694831 203.9%   
"Free" reserves Rs m19,704155,157 12.7%   
Net worth Rs m21,398155,988 13.7%   
Long term debt Rs m21,304 0.2%   
Total assets Rs m39,113232,253 16.8%  
Interest coverage x1,091.019.6 5,562.8%   
Debt to equity ratio x00 1.1%  
Sales to assets ratio x0.80.8 106.0%   
Return on assets %11.49.1 124.7%  
Return on equity %20.813.0 160.3%  
Return on capital %31.912.6 253.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53484,193 0.6%   
Fx outflow Rs m7,09139,616 17.9%   
Net fx Rs m-6,55744,577 -14.7%   
CASH FLOW
From Operations Rs m3,99429,841 13.4%  
From Investments Rs m-1,433-4,923 29.1%  
From Financial Activity Rs m-3,584-25,159 14.2%  
Net Cashflow Rs m-1,023-266 384.7%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 5.4 188.9%  
FIIs % 23.8 35.3 67.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 15.4 15.3 100.7%  
Shareholders   102,036 75,885 134.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ALEMBIC  SUN PHARMA  PIRAMAL ENTERPRISES  FDC  NEULAND LABS  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Apr 19, 2021 03:36 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS